Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$103.03 USD

103.03
5,547,306

-1.80 (-1.72%)

Updated Aug 6, 2025 02:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

DaVita Stock Down Despite Q1 Earnings Beat, Margins Contract

by Zacks Equity Research

Strength in revenue per treatment and dialysis patient service revenues drives DVA's first-quarter 2025 performance despite a year-over-year decline in normalized non-acquired treatment.

Zacks Equity Research

Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase

by Zacks Equity Research

PBH experiences steady international growth in the fourth quarter, banking on strong sales of the Hydralyte brand.

Zacks Equity Research

GEHC Stock Surges as SIGNA Sprint MRI Redefines 1.5T Imaging Tech

by Zacks Equity Research

GE HealthCare unveils SIGNA Sprint MRI, a high-performance 1.5T system designed to boost diagnostic accuracy, accelerate imaging, and advance cardiac and cancer care.

Zacks Equity Research

Should You Continue to Retain DGX Stock in Your Portfolio?

by Zacks Equity Research

Quest Diagnostics continues to stay on investors' radars due to its robust Advanced Diagnostics offerings and strength in acquisitions.

Zacks Equity Research

PACB Stock May Rise Following the Deal With Chulalongkorn University

by Zacks Equity Research

PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand.

Zacks Equity Research

PAHC or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PAHC vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

Are Medical Stocks Lagging Bayer (BAYRY) This Year?

by Zacks Equity Research

Here is how Bayer Aktiengesellschaft (BAYRY) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Zacks Equity Research

Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised

by Zacks Equity Research

PODD delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up

by Zacks Equity Research

Haemonetics' fourth-quarter fiscal 2025 results reflect the positive impact of its long-term plan, with meaningful earnings growth and margin expansion.

Zacks Equity Research

GMED Q1 Earnings & Revenues Miss, '25 EPS View Down, Stock Falls

by Zacks Equity Research

GMED's first-quarter 2025 weak performance reflects soft Enabling Technology deal closures.

Zacks Equity Research

Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up

by Zacks Equity Research

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.

Zacks Equity Research

TMDX Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down

by Zacks Equity Research

Increased organ utilization in liver and continued OCS adoption across both liver and heart boosted TransMedics' first-quarter 2025 performance.

Zacks Equity Research

AMN Stock Gains Following Q1 Earnings & Revenue Beat, Margins Down

by Zacks Equity Research

AMN Healthcare's dismal results in all its segments led to a soft overall first-quarter 2025 performance.

Zacks Equity Research

PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates

by Zacks Equity Research

Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system shipments.

Zacks Equity Research

Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips

by Zacks Equity Research

ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025.

Urmimala Biswas headshot

Is Medtronic Stock a Buy Pre-Q4 Earnings? Key Metrics to Watch

by Urmimala Biswas

Despite challenges, Medtronic demonstrates the resilience of its underlying business fundamentals, delivering consistent mid-single-digit organic revenue growth.

Zacks Equity Research

QuidelOrtho Stock Gains Following Q1 Earnings Beat, Margins Expand

by Zacks Equity Research

Despite solid performances by the Labs and Immunohematology units and EMEA and Other regions, QDEL reports soft overall top-line results in first-quarter 2025.

Zacks Equity Research

INGN Stock Gains Following Q1 Earnings Beat, Revenues Up Y/Y

by Zacks Equity Research

Inogen's overall first-quarter 2025 results continue to gain from higher business-to-business sales.

Zacks Equity Research

XRAY Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down

by Zacks Equity Research

DENTSPLY SIRONA's customer-centric innovation and operational efficiency drive its first-quarter 2025 performance despite global macroeconomic challenges.

Zacks Equity Research

Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Boston Scientific (BSX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Phibro Q3 Earnings Top Estimates, Stock Up, 2025 EPS Outlook Raised

by Zacks Equity Research

PAHC's third-quarter fiscal 2025 results reflect the strength of the Animal Health segment.

Zacks Equity Research

Bruker Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Crash

by Zacks Equity Research

Bruker delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

EYE Q1 Earnings and Revenues Beat, Gross Margin Up, Stock Surges

by Zacks Equity Research

Continued strength in Managed Care aids National Vision's first-quarter 2025 performance.

Zacks Equity Research

QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up

by Zacks Equity Research

QGEN's quarterly performance benefits from a resilient portfolio in the first quarter of 2025.

Urmimala Biswas headshot

Abbott Outpaces Peers Defying Tariff Woes: Is ABT Stock a Smart Buy?

by Urmimala Biswas

Despite trade policy challenges, Abbott's global footprint and 90 manufacturing sites offer flexibility to manage regional risks and reroute supply chains.